In solid-phase production of therapeutic peptides that carry a D-serine residue at the N-terminus or in internal positions to reduce exopeptidase degradation, Cbz-D-Ser-OH is employed as an N-urethane-protected amino acid building block. The protected monomer is coupled onto the deprotected amino terminus of the growing peptide chain in a jacketed glass reactor with nitrogen purging at a resin substitution of 0.3–0.8 mmol/g in DMF. It is charged at 1.05–1.25 molar equivalents relative to free amino groups; activation uses diisopropylcarbodiimide and ethyl cyanohydroxyiminoacetate at 1.1–1.5 equivalents relative to the carboxyl group, with reaction temperature maintained at 20–25°C for 2–4 h. Completion is confirmed by Kaiser test; if the test remains positive after recoupling, the resin is capped with acetic anhydride. The N-benzyloxycarbonyl group is removed under catalytic hydrogenation using 10% palladium on carbon at 25–30°C and 0.3–0.5 MPa hydrogen pressure, or by transfer hydrogenation with ammonium formate as hydrogen donor when static autoclave access is restricted. This deprotection step requires reactor inertization because hydrogen and powdered catalyst form a flammable mixture; spent palladium catalyst is recovered by filtration through a sparkler filter. The terminal D-serine-containing peptide API is cleaved from the resin, precipitated with cold methyl tert-butyl ether, and lyophilized into sterile vials. Compliance is governed by ICH Q7 Chapters 7 and 12, 21 CFR 211.160 for laboratory controls, and Ph. Eur. 2.2.46 for HPLC purity assessment. Terminal finished dosage types include lyophilized peptide vials for reconstitution, pre-filled syringes for chronic endocrine conditions, and implantable peptide depots where D-serine residues confer metabolic stability.

What Limits Solution-Phase Coupling Efficiency of N-Benzyloxycarbonyl-D-serine in Generic Peptide API Routes?

When Cbz-D-Ser-OH is activated as a mixed anhydride in tetrahydrofuran, the carboxyl group becomes susceptible to both amine coupling and intramolecular O-acylation because the free β-hydroxyl side chain can compete for the activated carbonyl. In solution-phase assembly of generic peptide APIs, Cbz-D-Ser-OH is used for the production of protected dipeptide and tripeptide fragments; the carboxyl function is pre-activated with isobutyl chloroformate and N-methylmorpholine in tetrahydrofuran at -15 to -20°C, and the amino component is added at 1.05–1.35 molar equivalents per activated carboxyl. Activation temperature must be maintained below 0°C because O-acylated and β-lactone impurities, which require preparative HPLC for removal, increase above this threshold. The mixed anhydride route is preferred over carbodiimide/hydroxybenzotriazole activation in this scenario because the latter produces dicyclohexylurea that complicates filtration at multi-kilo scale. After coupling, the Cbz group is cleaved by hydrogenolysis over 5% Pd/C in methanol at 25°C under 0.2–0.4 MPa H₂; sulfur-containing substrates are excluded because thioether and thiol groups poison the palladium surface. Compliance for residual solvents follows ICH Q3C and USP <467>; residual isobutyl chloroformate byproducts are tracked by GC according to Ph. Eur. 2.2.28. Downstream production includes aqueous workup at pH 8–9, extraction into ethyl acetate, vacuum distillation at jacket temperature not exceeding 40°C, and crystallization from n-heptane/ethyl acetate. Terminal finished products are generic injectable peptide APIs supplied as lyophilized powder in single-dose vials and cartridge-based pen systems for diabetes and hormone therapy.

Conversion of N-benzyloxycarbonyl-D-serine to D-serine methyl ester hydrochloride begins with slow addition of thionyl chloride to a methanolic solution of Cbz-D-Ser-OH at 0–5°C in a glass-lined reactor equipped with a caustic scrubber for HCl and SO₂ off-gas. Thionyl chloride is charged at 1.2–1.5 molar equivalents per carboxyl group; after addition, the batch is heated to 60–65°C and held for 6–8 h. The intermediate Cbz-D-serine methyl ester is concentrated under vacuum at 40°C, diluted with methyl tert-butyl ether, and washed with sodium bicarbonate solution to remove acid residues. Simultaneous Cbz deprotection and salt formation are performed by hydrogenolysis over 5% Pd/C in methanolic HCl at 25–30°C and 0.2–0.4 MPa; the catalyst is filtered through a plate filter, and the filtrate is concentrated to a slurry. D-serine methyl ester hydrochloride is isolated by filtration, washed with cold isopropanol, and dried under vacuum at 35–40°C to residual water below 0.5%. A purity of at least 98.5% by HPLC area percent is targeted, with residual Cbz-D-serine controlled below 0.1% and benzyl alcohol below 0.3% according to USP <621> and USP <467>. The process is operated under ISO 9001:2015 and a REACH-compliant substance identity profile, with safety data sheets aligned to Regulation (EC) No 1907/2006 Annex II. Terminal downstream product types include D-serine methyl ester hydrochloride as a chiral building block for peptide APIs and small-molecule pharmaceutical intermediates.

When D-Serine Methyl Ester Hydrochloride Is Advanced to D-Cycloserine API in Multidrug-Resistant Tuberculosis Therapy

The route from D-serine methyl ester hydrochloride to D-cycloserine proceeds by freebasing the hydrochloride with sodium methoxide in methanol at 0–10°C, followed by addition of hydroxylamine hydrochloride at 1.1–1.5 molar equivalents relative to the ester. The cyclization is kept at 25–35°C for 12–24 h under nitrogen, with pH held at 9–10 using additional sodium methoxide; the resulting D-cycloserine is extracted into ethyl acetate after saturation with sodium chloride, and crystallized from ethanol/water. The upstream Cbz-D-serine route provides the chiral starting material with a Cbz-protected amino group that suppresses racemization during esterification; this is a key process control advantage in multi-kilo D-cycloserine campaigns. Published data for the exact cyclization ratio at production scale is limited; the cited range reflects pilot campaigns using the equipment described. Compliance in this segment is governed by WHO GMP as described in WHO Technical Report Series No. 957, Annex 2, and the USP Cycloserine monograph; residual hydroxylamine is controlled by a validated HPLC method meeting ICH Q2(R1) requirements for linearity and accuracy. The final API is micronized to a particle size distribution with D90 ≤ 30 µm in a jet mill under nitrogen. Terminal finished product types are cycloserine capsules and film-coated tablets at 250 mg and 125 mg strengths, packaged in HDPE bottles with desiccant for the WHO-recommended multidrug-resistant tuberculosis regimen.

Cosmetic Peptide Active Ingredient Synthesis Routes Using D-Serine Residues

In cosmetic peptide manufacture, Cbz-D-Ser-OH is incorporated as an N-protected chiral building block into synthetic peptides that contain D-serine residues to resist cleavage by skin aminopeptidases and prolong activity in leave-on formulations. The peptide synthesis is performed by solid-phase or solution-phase methods, with Cbz-D-Ser-OH charged at 1.05–1.20 molar equivalents relative to the resin amino groups or peptide amino terminus; coupling is conducted in DMF at 20–25°C for 2–3 h using carbodiimide/Oxyma activation. The protected peptide is cleaved and purified by preparative RP-HPLC to a purity of 95.0–99.0% by area, then lyophilized. The final cosmetic peptide, not the Cbz-D-Ser-OH raw material, is added to emulsions and serums at 0.5–5.0 ppm peptide active; the raw protected amino acid is not present in the finished cosmetic because the Cbz group is removed during peptide cleavage and subsequent purification. Compliance is framed by Regulation (EC) No 1223/2009 Article 10 product safety assessment and ISO 22716 for cosmetic GMP; if the peptide is marketed with a natural origin claim, ISO 16128 applies to the final formula. The downstream production process includes sterile filtration through 0.22 µm filters, aseptic filling into airless pumps, and compatibility testing at 40°C/75% RH for 3 months with peptide content monitored by HPLC. Terminal finished product types include anti-wrinkle serums, eye creams, sheet masks, and scalp ampoules containing D-serine-modified peptides as active ingredients.